CA2861661C - Improved synergistic anti-diabetic compositions - Google Patents

Improved synergistic anti-diabetic compositions Download PDF

Info

Publication number
CA2861661C
CA2861661C CA2861661A CA2861661A CA2861661C CA 2861661 C CA2861661 C CA 2861661C CA 2861661 A CA2861661 A CA 2861661A CA 2861661 A CA2861661 A CA 2861661A CA 2861661 C CA2861661 C CA 2861661C
Authority
CA
Canada
Prior art keywords
inulin
sulfonylurea
sulfonamide
diabetes
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861661A
Other languages
English (en)
French (fr)
Other versions
CA2861661A1 (en
Inventor
Nick Naser Gorgani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ozstar Therapeutics Pty Ltd
Original Assignee
Ozstar Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904887A external-priority patent/AU2011904887A0/en
Application filed by Ozstar Therapeutics Pty Ltd filed Critical Ozstar Therapeutics Pty Ltd
Publication of CA2861661A1 publication Critical patent/CA2861661A1/en
Application granted granted Critical
Publication of CA2861661C publication Critical patent/CA2861661C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2861661A 2011-11-23 2012-11-23 Improved synergistic anti-diabetic compositions Active CA2861661C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2011904887A AU2011904887A0 (en) 2011-11-23 Improved synergistic anti-diabetic compositions
AU2011904887 2011-11-23
AU2012902723 2012-06-27
AU2012902723A AU2012902723A0 (en) 2012-06-27 Improved synergistic anti-diabetic compositions -II
PCT/AU2012/001442 WO2013075172A1 (en) 2011-11-23 2012-11-23 Improved synergistic anti-diabetic compositions

Publications (2)

Publication Number Publication Date
CA2861661A1 CA2861661A1 (en) 2013-05-30
CA2861661C true CA2861661C (en) 2021-03-16

Family

ID=48468910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861661A Active CA2861661C (en) 2011-11-23 2012-11-23 Improved synergistic anti-diabetic compositions

Country Status (11)

Country Link
US (1) US9737559B2 (enExample)
EP (1) EP2782586A4 (enExample)
JP (2) JP2014533702A (enExample)
KR (1) KR102104384B1 (enExample)
CN (1) CN104244958B (enExample)
AU (1) AU2012343332B2 (enExample)
BR (1) BR112014012401A2 (enExample)
CA (1) CA2861661C (enExample)
IN (1) IN2014KN01304A (enExample)
RU (1) RU2642633C2 (enExample)
WO (1) WO2013075172A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498611B (zh) * 2019-01-15 2020-09-01 张惊宇 一种治疗糖尿病周围神经痛的药物及其用途
RU2741079C1 (ru) * 2020-04-06 2021-01-22 Общество С Ограниченной Ответственностью "Технологии Дкв" Пищевая добавка «пребио дкв»

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082842A (en) * 1975-02-21 1978-04-04 Armando Nahle Medicant composition for the treatment of diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
EP1310173B2 (en) * 1997-06-23 2014-12-31 Société des Produits Nestlé S.A. Composition for providing nutrition to diabetics
US20030130205A1 (en) 2000-04-12 2003-07-10 Christian Samuel T. Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
WO2004070009A2 (en) * 2003-01-31 2004-08-19 Targesome Inc. Targeted multivalent macromolecules
CN1921881A (zh) * 2003-10-27 2007-02-28 因诺迪亚公司 羟基化氨基酸用于治疗糖尿病的用途
JP2006052191A (ja) * 2004-08-16 2006-02-23 Taiyo Kagaku Co Ltd 糖尿病予防、改善、または治療用組成物
CN1861173A (zh) * 2005-05-13 2006-11-15 王锦 糖尿病人营养治疗药品膳食纤维素粉产品
EP1893041A4 (en) 2005-06-17 2009-05-13 Henry H Ottens Mfg Company Inc FIBER-REINFORCED CEREALS, CEREAL BARS AND FOODS AND METHODS OF MAKING
EP1832179B1 (en) * 2005-12-20 2018-11-07 N.V. Nutricia Carbohydrate composition and flat glucose response
ATE529093T1 (de) * 2007-05-10 2011-11-15 Oreal Kosmetische zusammensetzung mit einem inulinderivat in form einer volumsexpandierten emulsion
US20090214511A1 (en) * 2008-02-21 2009-08-27 Trung Hong Tran Digestible compositions of inulin for managing blood glucose levels
GB0907019D0 (en) * 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
WO2010124387A1 (en) 2009-05-01 2010-11-04 Micropharma Limited Bacterial compositions for prophylaxis and treatment of degenerative disease
US9241952B2 (en) * 2010-05-24 2016-01-26 Ozstar Therapeutics Pty Ltd Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin

Also Published As

Publication number Publication date
CA2861661A1 (en) 2013-05-30
EP2782586A4 (en) 2015-07-01
JP2017226672A (ja) 2017-12-28
CN104244958B (zh) 2017-11-17
KR20150002575A (ko) 2015-01-07
WO2013075172A1 (en) 2013-05-30
RU2642633C2 (ru) 2018-01-25
JP6609287B2 (ja) 2019-11-20
BR112014012401A2 (pt) 2017-06-13
IN2014KN01304A (en) 2015-10-16
EP2782586A1 (en) 2014-10-01
RU2014125249A (ru) 2015-12-27
CN104244958A (zh) 2014-12-24
AU2012343332A1 (en) 2014-07-17
AU2012343332B2 (en) 2017-03-16
JP2014533702A (ja) 2014-12-15
US20140303118A1 (en) 2014-10-09
US9737559B2 (en) 2017-08-22
KR102104384B1 (ko) 2020-04-27

Similar Documents

Publication Publication Date Title
US12527810B2 (en) Pharmaceutical composition, methods for treating and uses thereof
DK2395984T3 (en) PHARMACEUTICAL COMPOSITION COMPREHENSIVE linagliptin AND A SGLT2 INHIBITOR AND USE THEREOF
JP4659358B2 (ja) 経口インスリン療法
JP5600328B2 (ja) グルコピラノシルジフェニルメタン誘導体を含む医薬組成物、その医薬剤形、それらの調製方法及び患者の血糖コントロールを改善するためのそれらの使用
JP2012523374A (ja) Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
CN105380962B (zh) 一种降尿酸组合物及其制剂
EP1501498A1 (en) Pharmaceutical composition comprising a lipase inhibitor and glucomannan
US9737559B2 (en) Synergistic anti-diabetic compositions
CN1327840C (zh) 一种药物组合物及其在制备用于治疗糖尿病中的应用
CN101244062A (zh) 持续释放药用组合物及其用途
Young et al. Pharmacologic Management of Type 2 Diabetes Mellitus: Part 2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171108

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241111

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241111

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251110